Jazz Pharmaceuticals plc
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Arrangements
The following is a summary of the material terms of the contracts, instructions or written plans for the purchase or sale of the Company’s securities adopted orterminated by our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors during the quarter ended June 30, 2026:
Type of Trading Arrangement
| Name and Position | Date | Action | Rule 10b5-1* | Expiration Date | Total Ordinary Shares to be Sold |
|---|---|---|---|---|---|
| Robert Iannone(Executive Vice President, Global Head of Research and Development, Chief Medical Officer) | 5/28/2026 | Adoption | X | 5/28/2027, or such earlier date upon which all transactions are completed or expire without execution | Indeterminable(1) |
| Renee D. Gala(President and Chief Executive Officer) | 6/4/2026 | Adoption | X | 8/5/2027, or such earlier date upon which all transactions are completed | Up to 7,400 |
| Mark D. Smith(Director) | 6/15/2026 | Termination | X | 12/31/2026 | 1,157 |
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act
(1) Dr. Iannone's Rule 10b5-1 Trading Plan provides for the (i) same-day exercise and sale of up to 53,700 stock options, (ii) sale of up to 16,038 ordinary shares, (iii) sale of an indeterminable number of ordinary shares sufficient to cover stock option exercise costs and estimated tax withholding amounts and customary brokerage fees, and (iv) sale of an indeterminable number of ordinary shares from the settlement of RSUs and PSUs. The number of ordinary shares in clauses (iii) and (iv) are indeterminable because the numbers will vary based on the extent to which vesting, performance or exercise conditions are satisfied, the market price of the Company's ordinary shares at the time of settlement and the number of shares that would otherwise be issuable on each settlement date of a covered stock option, RSU or PSU that are sold or withheld in an amount sufficient to satisfy the applicable tax withholding obligations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.